Cullinan Therapeutics (CGEM) EBIT Margin (2021)
Historic EBIT Margin for Cullinan Therapeutics (CGEM) over the last 1 years, with Q1 2021 value amounting to 7.24%.
- Cullinan Therapeutics' EBIT Margin changed N/A to 7.24% in Q1 2021 from the same period last year, while for Dec 2021 it was 358.73%, marking a year-over-year change of. This contributed to the annual value of 358.73% for FY2021, which is N/A changed from last year.
- According to the latest figures from Q1 2021, Cullinan Therapeutics' EBIT Margin is 7.24%.
- Cullinan Therapeutics' EBIT Margin's 5-year high stood at 7.24% during Q1 2021, with a 5-year trough of 7.24% in Q1 2021.